Epilepsy, Idiopathic Generalized clinical trials
The registry lists 35 studies for Epilepsy, Idiopathic Generalized across more than 10 countries. 4 are recruiting or about to start. 22 of them are mainly about Epilepsy, Idiopathic Generalized (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Epilepsy, Idiopathic Generalized studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis (4) · UCB BIOSCIENCES, Inc. (4) · SK Life Science, Inc. (2) · Mazandaran University of Medical Sciences (2) · Novartis Pharmaceuticals (2) · UCB Pharma (2) · University of Alabama at Birmingham (1) · University Hospital, Lille (1)
What is being tested here
Drugs under test in Epilepsy, Idiopathic Generalized studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Omalizumab | 0 | 2 | 5 |
| Lacosamide | 0 | 2 | 4 |
| Levetiracetam | 0 | 2 | 3 |
| Cenobamate | 0 | 2 | 2 |
| Suvecaltamide | 0 | 0 | 1 |
| Ligelizumab | 0 | 0 | 1 |
| PG-102 | 0 | 0 | 1 |
| Topiramate | 0 | 1 | 1 |
| Opakalim | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026Idiopathic Generalized Epilepsy Syndromes · Shen Chun-Hong
Who these studies take
Of the 3 Epilepsy, Idiopathic Generalized studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 2 (67%) | 2 (67%) |
| 65 | 2 (67%) | 2 (67%) |
| 75 | 1 (33%) | 1 (33%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 35 studies, recruiting or not: 60% stop at 75 or younger and 40% at 65; 57% take children; 0% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 35 of 35. search them.
- High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 YearsNot yet recruitingNCT07803692Not applicable1 country
- Idiopathic Generalized Epilepsy SyndromesRecruitingNCT063881741 country
- An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresRecruitingNCT06908356Phase 23 countries
- Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating RoomRecruitingNCT05420935Not applicable1 country
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresCompletedNCT03678753Phase 312 countries
- Cenobamate Open-Label Extension Study for YKP3089C025CompletedNCT03961568Phase 37 countries
- Human Epilepsy Project 3CompletedNCT053749282 countries
- RNS System NAUTILUS StudyCompletedNCT05147571Not applicable1 country
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic SeizuresTerminatedNCT06425159Phase 2/314 countries
- Exercise for Memory Rehabilitation in EpilepsyCompletedNCT04959019Not applicable1 country
- Blinking and Yawning in Epilepsy: The Role of DopamineCompletedNCT01432821Not applicable1 country
- Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.TerminatedNCT055301091 country
- Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe AsthmaActive, not recruitingNCT067719341 country
- Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.Active, not recruitingNCT06481280Not applicable2 countries
- Levetiracetam Versus Valproate in Idiopathic Generalized EpilepsyCompletedNCT063933091 country
- Genetic Disease Gene IdentificationTerminatedNCT009169031 country
- Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic SeizuresCompletedNCT02408549Phase 321 countries
- A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized EpilepsyCompletedNCT042528467 countries
- CX-8998 for Absence SeizuresCompletedNCT03406702Phase 21 country
- Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic SeizuresCompletedNCT03940326Phase 41 country
- A Study of Fycompa (Perampanel) in Korean ParticipantsCompletedNCT027225901 country
- A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic MedicationsCompletedNCT02408523Phase 322 countries
- Epilepsy Phenome/Genome ProjectCompletedNCT005520453 countries
- Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118962Phase 21 country
- Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118949Phase 21 country
- Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaCompletedNCT00267202Phase 41 country
- A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedNCT01703312Phase 1/22 countries
- Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic SeizuresCompletedNCT00160550Phase 3
- Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + AdultsCompletedNCT00150774Phase 3
- Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 47 countries
- Study of Omalizumab in Moderate to Severe Bronchial AsthmaCompletedNCT00232050Phase 3
- Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.CompletedNCT00219323Phase 31 country
- Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic UrticariaCompletedNCT00481676Phase 21 country
- The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE LevelsCompletedNCT01106703Phase 21 country
- Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy PatientsCompletedNCT00236886Phase 3